Evidence map›Paper›PMID 37941564›Full record

ArticleFrontiers in oncology2023

Establishment and validation of a nomogram to select patients with metastatic sarcomatoid renal cell carcinoma suitable for cytoreductive radical nephrectomy.

Yulin Zhou, Yufeng Gu, Chaopeng Tang, Jie Dong, Song Xu, Zhengcheng Sheng, Xiaodong Zhao, Jun Hu, Tianyi Shen, Haowei He and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yulin ZhouMedical College of Soochow University, Suzhou, China.
Yufeng GuDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Chaopeng TangDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jie DongDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Song XuDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Zhengcheng ShengDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiaodong ZhaoDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jun HuDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Tianyi ShenDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Haowei HeDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiaoming YiDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Wenquan ZhouDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Le QuDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jingping GeDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Conghui HanMedical College of Soochow University, Suzhou, China.
Nanjing General Hospital of Nanjing Military Command · CNNanjing Medical University · CNNanjing University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metastatic renal cell carcinoma (mRCC) with sarcomatoid features has a poor prognosis. Cytoreductive radical nephrectomy (CRN) can improve prognosis, but patient selection is unclear. This study aimed to develop a prediction model for selecting patients suitable for CRN. Materials and methods: Patients with a diagnosis of mRCC with sarcomatoid features in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 were retrospectively reviewed. CRN benefit was defined as a survival time longer than the median overall survival (OS) in patients who did not receive CRN. A prediction nomogram was established and validated using the SEER cohort (training and internal validation) and an external validation cohort. Results: Of 900 patients with sarcomatoid mRCC, 608 (67.6%) underwent CRN. OS was longer in the CRN group than in the non-CRN group (8 vs. 6 months, hazard ratio (HR) = 0.767, Conclusions: A nomogram was constructed and validated with good accuracy for selecting patients with sarcomatoid mRCC suitable for CRN.

Indexed as

cytoreductive radical nephrectomymetastaticnomogramprognosissarcomatoid renal cell carcinomaSEER database

Identifiers

PMID37941564
PMCPMC10627788
OpenAlexW4387868830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.